The Clinical Efficacy of Platelet-Rich Plasma Injection Therapy versus Different Control Groups for Chronic Low Back Pain: A Network Meta-Analysis of Randomized Controlled Trials
Xue Zhang,Aili Zhang,Hao Guan,Li Zhou,Jiao Zhang,Wenjie Yin
DOI: https://doi.org/10.2147/jpr.s444189
IF: 2.8319
2024-03-14
Journal of Pain Research
Abstract:Xue Zhang, 1, &ast Aili Zhang, 2, &ast Hao Guan, 1 Li Zhou, 1 Jiao Zhang, 3 Wenjie Yin 1 1 Department of Pharmacy, Kunming Yan'an Hospital, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650051, People's Republic of China; 2 Department of Scientific Research, Kunming Yan'an Hospital, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650051, People's Republic of China; 3 Department of Basic Medicine, Zhaotong Health Vocational College, Zhaotong, Yunnan, 657000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wenjie Yin; Xue Zhang, Department of Pharmacy, Kunming Yan'an Hospital, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650051, People's Republic of China, Email ; Objective: Low back pain is one of the main causes of disability in the world. Although regenerative medicine may represent breakthroughs in the management of low back pain, its use remains controversial. Therefore, we conducted a meta-analysis to evaluate the clinical efficacy of platelet-rich plasma (PRP) injection therapy versus different control groups for chronic low back pain during 4 weeks, 3 months, and 6 months. Methods: Different electronic databases were searched for randomized controlled trials up to August 2023. Mean changes from baseline in pain and Oswestry Disability Index (ODI) scores at 4 weeks, 3 months, and 6 months and standard deviations of outcome were recorded. Results: Four articles with 154 cases were finally included in this meta-analysis. After 4 weeks, corticosteroid (CS) was the optimal treatment option for chronic low back pain in terms of improvement in pain and disability index (surface under the cumulative ranking curve [SUCRA]=71.3%, SUCRA=57.8%, respectively). After 3 months, radiofrequency (RF) emerged as the best therapy in pain (SUCRA=100%) and disability index (SUCRA=98.5%), followed by PRP (SUCRA=62.3%, SUCRA=64.3%, respectively), CS (SUCRA=24.6%, SUCRA=25.9%, respectively) and lidocaine (SUCRA=13.1%, SUCRA=11.3%, respectively). At 6 months, RF was most likely to be the best treatment in pain (SUCRA=94.9%) and disability index (SUCRA=77.3%), followed by PRP (SUCRA=71.2%, SUCRA=79.6%, respectively). However, compared with the last follow-up, there was a slight downward trend in improvement pain and disability index with RF, while PRP was still an upward trend. Conclusion: This study demonstrated better short-term improvement of chronic low back pain with CS after 4 weeks. PRP and RF improvement effects matched, but follow-up of at least 6 months showed that PRP seemed to be more advantageous in improvement in disability indices. Considering the limitations of this study, these conclusions still need to be verified by more comparative RCTs and a longer follow-up period. Keywords: platelet-rich plasma, chronic low back pain, meta-analysis, randomized controlled trial, clinical efficacy Low back pain (LBP) is a highly prevalent symptom experienced by nearly everyone and is a leading cause of disability globally. 1,2 LBP is defined as pain (with or without pain in one or both legs) lasting at least one day, located posteriorly, ranging from the lower border of the 12th rib to the lower gluteal crease. 3–5 LBP symptoms can arise from various anatomical issues, including bones, nerve roots, fascial structures, joints, muscles, intervertebral discs, and abdominal organs. 6,7 Precisely defining the source of LBP is impossible for most patients. Nonspecific LBP accounts for approximately 90–95% of all cases. Improvement in approximately 75% of LBP patients is measured by increased pain and disability within 1 month, but in approximately 25% of cases, LBP is a chronic condition. 8 Chronic LBP is a prevalent issue on a global scale for which there is currently a lack of effective interventions to address this problem, leading to decreased physical activity and heightened disability. The increasing incidence of LBP imposes a heavy socioeconomic burden on patients and the healthcare sector, and worldwide, LBP is a leading cause of lost productivity and disability globally, with enormous socioeconomic and health impacts, 9,10 is now acknowledged as a critical public health concern. Therefore, patients with LBP require extensive multidisciplinary and multimodal care. 11,12 Platelet-rich plasma (PRP) is defined as autologous blood with a platelet concentration higher than the physiological baseline. It is prepared by centrifugation of the blood to obtain a concentrated solution of platelet. 13,14 Since its first -Abstract Truncated-
clinical neurology